



<b>SANDU PHARMACEUTICALS LIMITED</b> CIN: L24233GA1985PLC001587 <b>SANDU</b> REGD. OFFICE- PLOT NOS. 25, 26, 29 & 30, PILERNE INDUSTRIAL ESTATE, WARMA, SALIGAO, BARDEZ GOA- 403 511. <b>STATEMENT OF UNAUDITED RESULTS FOR THE YEAR ENDED 30/06/16</b>					
PART I					
(in Lacs)					
Particulars	3 months ended 30/06/16	3 months ended 31/03/16	Corresponding 3 months ended the previous year 30/06/15	Year to date figures for current period ended 30/06/16	Previous year ended 31/03/16
(Refer Notes Below)	(Unaudited)	(Audited)*	(Audited)	(Unaudited)	(Audited)
1 Income from continuing operations					
(a) Net sales/income from operations (Net of excise duty)	1,172.14	1,265.26	991.57	1,172.14	4,607.96
Less: Trade Discount	136.36	142.27	107.99	136.36	500.12
	1,035.78	1,122.98	883.58	1,035.78	4,107.84
(b) Other operating income					
<b>Total income from operations (net)</b>	<b>1,035.78</b>	<b>1,122.98</b>	<b>883.58</b>	<b>1,035.78</b>	<b>4,107.84</b>
2 Expenses					
(a) Cost of materials consumed	130.28	216.39	121.78	130.28	841.80
(b) Purchases of traded goods	429.51	287.25	514.39	429.51	1,344.63
(c) Changes in inventories of finished goods, work-in-progress, traded goods & Stock in Transit	8.35	13.68	-187.77	8.35	(57.75)
(d) Employee benefits expense	112.75	141.39	104.64	112.75	451.11
(e) Depreciation and amortisation expense	17.13	32.60	13.32	17.13	69.31
(f) Other expenses	276.64	378.26	269.84	276.64	1,240.97
<b>Total expenses</b>	<b>974.65</b>	<b>1,069.57</b>	<b>836.20</b>	<b>974.65</b>	<b>3,890.08</b>
3 Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	61.13	53.42	47.38	61.13	217.76
4 Other income	0.27	7.56	3.46	0.27	14.52
5 <b>Profit / (Loss) from ordinary activities</b>	<b>61.39</b>	<b>60.97</b>	<b>50.84</b>	<b>61.39</b>	<b>232.29</b>
before finance costs and exceptional items (3 + 4)					
6 Finance costs	40.35	42.30	34.08	40.35	164.34
7 <b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)</b>	<b>21.04</b>	<b>18.67</b>	<b>16.76</b>	<b>21.04</b>	<b>67.94</b>
8 Exceptional items					
9 <b>Profit / (Loss) from ordinary activities before tax (7 + 8)</b>	<b>21.04</b>	<b>18.67</b>	<b>16.76</b>	<b>21.04</b>	<b>67.94</b>
10 Tax expense	7.65	0.79	3.62	7.65	14.15
11 <b>Net Profit / (Loss) from ordinary activities after tax (9 + 10)</b>	<b>13.39</b>	<b>17.88</b>	<b>13.14</b>	<b>13.39</b>	<b>53.79</b>
12 Extraordinary items (net of tax expense)		0.00	0.00	0.00	0.00
13 <b>Net Profit / (Loss) for the period (11 + 12)</b>	<b>13.39</b>	<b>17.88</b>	<b>13.14</b>	<b>13.39</b>	<b>53.79</b>
14 Share of profit / (loss) of associates*	0.00	0.00	0.00	0.00	0.00
15 Minority interest *					
16 <b>Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *</b>	<b>13.39</b>	<b>17.88</b>	<b>13.14</b>	<b>13.39</b>	<b>53.79</b>
17 Paid-up equity share capital (Face Value of the Share shall be indicated)	708.10	708.10	708.10	708.10	708.10
18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	1,173.66	1,160.27	1,119.61	1,173.66	1,160.27
19.i Earnings per share (before extraordinary items) (of 10/- each) (not annualised):	0.19	0.25	0.19	0.19	0.76
(a) Basic					
(b) Diluted					
19.ii Earnings per share (after extraordinary items) (of 10/- each) (not annualised):	0.19	0.25	0.19	0.19	0.76
(a) Basic					
(b) Diluted					
<b>Notes to Accounts</b> 1. The Auditors have conducted Limited Review of the financial results for the quarter ended June 30, 2016. The Unaudited Financial results have been recommended by the audit committee at its meeting held on August 13, 2016 and Approved by the Board of Directors at its meeting held on August 13, 2016. 2. In view of favorable decision, the company is entitled to get the refund of partial payment of income tax alongwith interest u/s 244 (A) of the Income Tax 1961. Since the order giving effect to the appellate order is not yet been passed by the Assessing officer the interest is not yet accrued & as such does not form part of income hence not reflected in statement of unaudited results					
<div style="display: flex; justify-content: space-between; align-items: flex-end;"> <div>           PLACE: MUMBAI            DATE : 13/08/16         </div> <div style="text-align: center;">  </div> <div style="text-align: right;">           For SANDU PHARMACEUTICALS LIMITED              UMESH B. SANDU            MANAGING DIRECTOR            DIN:- 01132141         </div> </div>					

### Limited Review Report


"We have reviewed the accompanying statement of un-audited financial results of M/S Sandu Pharmaceuticals Limited for the period ended 30<sup>th</sup> June 2016. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

"We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

"Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of un-audited financial results prepared in accordance with accounting standards in India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulation 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement."



For JOSHI JOSHI & Co.  
Chartered Accountants

  
(M. M. Joshi)

Place Mumbai  
Proprietor  
Date 13/08/2016

(M. No. 042466)